Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kewaunee Scientific (KEQU) Cash & Equivalents (2016 - 2026)

Kewaunee Scientific (KEQU) has 16 years of Cash & Equivalents data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 95.82% year-over-year to $1.1 million; the TTM value through Oct 2025 reached $1.1 million, down 95.82%, while the annual FY2025 figure was $14.9 million, 459.42% up from the prior year.
  • Cash & Equivalents reached $1.1 million in Q4 2025 per KEQU's latest filing, up from $952000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $26.0 million in Q4 2024 and bottomed at $525000.0 in Q2 2021.
  • Average Cash & Equivalents over 5 years is $5.7 million, with a median of $4.8 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: surged 1052.88% in 2022, then crashed 95.82% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $817000.0 in 2021, then soared by 1052.88% to $9.4 million in 2022, then decreased by 15.18% to $8.0 million in 2023, then soared by 224.98% to $26.0 million in 2024, then plummeted by 95.82% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.1 million in Q4 2025, $952000.0 in Q3 2025, and $14.9 million in Q2 2025.